Base-case input parameters and their probability distributions for PSA
| Result or transition . | Input parameter . | Probability distribution . | Study or data source . |
|---|---|---|---|
| Probability of iTTP based on PLASMIC (6-7) | 0.81 | β-PERT (0.41, 1) | Bendapudi et al5 |
| Probability of iTTP based on PLASMIC (5) | 0.045 | β-PERT (0.023, 0.068) | Bendapudi et al5 |
| Daily mortality in patients with iTTP with caplacizumab and TPE (converted to daily using a conservative median per-person treatment period of 35 d) | 0.000266 | β-PERT (0.00013, 0.00040) | Peyvandi et al18 |
| Daily mortality in patients without iTTP patients with TPE | 0.00411 | β-PERT (0.0021,0.0.0062) | Li et al19 |
| Daily probability of ISTH-defined major bleeding with caplacizumab (converted to daily using a conservative median per-person treatment period of 35 d across available real-world reports) | .000592 | β-PERT (0.000296, 0.000888) | Coppo et al, Dutt et al, and Knobl et al20-22 |
| Daily probability of ICH with caplacizumab (converted to daily using a conservative median per-person treatment period of 35 d across available real-world reports) | .000423 | β-PERT (0.000212, 0.000635) | Dutt et al, Knobl et al, and Izquierdo et al21-23 |
| Mortality of (ISTH-defined) non-ICH major bleeding | 0.00440 | β-PERT (0.0022, 0.0066) | Franco et al24 |
| Mortality of ICH | 0.00758 | β-PERT (0.0038, 0.011) | Franco et al24 |
| Probability of TRALI | 0.0000833 | β-PERT (0.000042, 0.00013) | Pandey et al25 |
| Probability of TACO | 0.000639 | β-PERT (0.00032, 0.00096) | Narick et al26 |
| Daily probability of severe anaphylaxis | 0.000000606 | β-PERT (0.0000003, 0.0000009) | Som et al27 |
| Daily probability of catheter thrombosis | 0.0000106 | β-PERT (0.0000053, 0.000016) | Som et al27 |
| Daily probability of central line infection | 0.0000218 | β-PERT (0.000011, 0.000033) | Som et al27 |
| Daily mortality of TRALI | 0.00107 | β-PERT (0.00054, 0.0016) | Li et al28 |
| Daily mortality of TACO | 0.000410 | β-PERT (0.0002, 0.006) | Li et al28 |
| Daily mortality of central line infection | 0.0568 | β-PERT (0.028, 0.085) | Ziegler et al29 |
| Costs | |||
| Caplacizumab dose (11 mg) | 8 112.62 | Fixed | CMS 202330,31 |
| TPE, per session (professional and technical cost) | 5 573.47 | Gamma (36, 154.82) | Average of all 3 US reports: White et al, Connell et al, Goshua et al, and Kim et al10,31-33 |
| ICU bed per day | 1 291.3 | Gamma (36, 35.87) | Goshua et al31 |
| Rapid testing (HemosIL Acustar ADAMTS13 activity) | 546.02 | Gamma (36, 15.17) | White et al32 |
| In-house testing | 442.51 | Gamma (36, 12.29) | Kim et al9 |
| Send-out testing | 582.85 | Gamma (36, 16.19) | Kim et al9 |
| iTTP hospitalization without complications | 6 667.84 | Gamma (36, 185.22) | MS-DRG 81034 |
| iTTP hospitalization with a complication (nonmajor) | 8 482.30 | Gamma (36, 235.62) | MS-DRG 80934 |
| iTTP hospitalization with a major complication (ie, ICH) | 15 155.00 | Gamma (36, 420.97) | MS-DRG 80834 |
| Result or transition . | Input parameter . | Probability distribution . | Study or data source . |
|---|---|---|---|
| Probability of iTTP based on PLASMIC (6-7) | 0.81 | β-PERT (0.41, 1) | Bendapudi et al5 |
| Probability of iTTP based on PLASMIC (5) | 0.045 | β-PERT (0.023, 0.068) | Bendapudi et al5 |
| Daily mortality in patients with iTTP with caplacizumab and TPE (converted to daily using a conservative median per-person treatment period of 35 d) | 0.000266 | β-PERT (0.00013, 0.00040) | Peyvandi et al18 |
| Daily mortality in patients without iTTP patients with TPE | 0.00411 | β-PERT (0.0021,0.0.0062) | Li et al19 |
| Daily probability of ISTH-defined major bleeding with caplacizumab (converted to daily using a conservative median per-person treatment period of 35 d across available real-world reports) | .000592 | β-PERT (0.000296, 0.000888) | Coppo et al, Dutt et al, and Knobl et al20-22 |
| Daily probability of ICH with caplacizumab (converted to daily using a conservative median per-person treatment period of 35 d across available real-world reports) | .000423 | β-PERT (0.000212, 0.000635) | Dutt et al, Knobl et al, and Izquierdo et al21-23 |
| Mortality of (ISTH-defined) non-ICH major bleeding | 0.00440 | β-PERT (0.0022, 0.0066) | Franco et al24 |
| Mortality of ICH | 0.00758 | β-PERT (0.0038, 0.011) | Franco et al24 |
| Probability of TRALI | 0.0000833 | β-PERT (0.000042, 0.00013) | Pandey et al25 |
| Probability of TACO | 0.000639 | β-PERT (0.00032, 0.00096) | Narick et al26 |
| Daily probability of severe anaphylaxis | 0.000000606 | β-PERT (0.0000003, 0.0000009) | Som et al27 |
| Daily probability of catheter thrombosis | 0.0000106 | β-PERT (0.0000053, 0.000016) | Som et al27 |
| Daily probability of central line infection | 0.0000218 | β-PERT (0.000011, 0.000033) | Som et al27 |
| Daily mortality of TRALI | 0.00107 | β-PERT (0.00054, 0.0016) | Li et al28 |
| Daily mortality of TACO | 0.000410 | β-PERT (0.0002, 0.006) | Li et al28 |
| Daily mortality of central line infection | 0.0568 | β-PERT (0.028, 0.085) | Ziegler et al29 |
| Costs | |||
| Caplacizumab dose (11 mg) | 8 112.62 | Fixed | CMS 202330,31 |
| TPE, per session (professional and technical cost) | 5 573.47 | Gamma (36, 154.82) | Average of all 3 US reports: White et al, Connell et al, Goshua et al, and Kim et al10,31-33 |
| ICU bed per day | 1 291.3 | Gamma (36, 35.87) | Goshua et al31 |
| Rapid testing (HemosIL Acustar ADAMTS13 activity) | 546.02 | Gamma (36, 15.17) | White et al32 |
| In-house testing | 442.51 | Gamma (36, 12.29) | Kim et al9 |
| Send-out testing | 582.85 | Gamma (36, 16.19) | Kim et al9 |
| iTTP hospitalization without complications | 6 667.84 | Gamma (36, 185.22) | MS-DRG 81034 |
| iTTP hospitalization with a complication (nonmajor) | 8 482.30 | Gamma (36, 235.62) | MS-DRG 80934 |
| iTTP hospitalization with a major complication (ie, ICH) | 15 155.00 | Gamma (36, 420.97) | MS-DRG 80834 |
CMS, Centers for Medicare and Medicaid Services; ICH, intracranial hemorrhage; ISTH, International Society on Thrombosis and Haemostasis; TRALI, transfusion-related acute lung injury; TACO, transfusion-associated cirulatory overload.